BRKR:NSD-Bruker Corporation (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 61.81

Change

-0.19 (-0.31)%

Market Cap

USD 9.18B

Volume

0.56M

Avg Analyst Target

USD 60.00 (-2.93%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


BRKR Stock Forecast & Price:
Based on the Bruker Corporation stock forecasts from 1 analysts, the average analyst target price for Bruker Corporation is USD 60.00 over the next 12 months. Bruker Corporation’s average analyst rating is Sell. Stock Target Advisor’s own stock analysis of Bruker Corporation is Slightly Bullish , which is based on 9 positive signals and 6 negative signals. At the last closing, Bruker Corporation’s stock price was USD 61.81. Bruker Corporation’s stock price has changed by -1.07% over the past week, -3.44% over the past month and -25.24% over the last year.

About Bruker Corporation (BRKR:NSD)

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-12 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

+1.59 (+1.80%)

USD34.96B 205.21 88.80
PODD Insulet Corporation

+6.62 (+2.51%)

USD18.33B 498.26 127.76
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
ABMD ABIOMED Inc

+2.66 (+0.91%)

USD13.28B 58.91 43.54
SWAV Shockwave Medical Inc

+7.61 (+2.70%)

USD10.03B 341.73 123.23
IART Integra LifeSciences Holdings

+0.89 (+1.58%)

USD4.72B 28.97 16.36
IRTC iRhythm Technologies Inc

-0.38 (-0.25%)

USD4.56B N/A -39.96
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67
TNDM Tandem Diabetes Care Inc

+0.33 (+0.62%)

USD3.64B 707.88 556.41
LIVN LivaNova PLC

+1.17 (+1.84%)

USD3.40B 77.40 45.55

ETFs Containing BRKR

Symbol Name Weight Mer Price(Change) Market Cap
RNMC First Trust Mid Cap US Eq.. 0.00 % 0.60 %

+0.45 (+1.60%)

USD0.02B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -26.34% 58% F 38% F
Dividend Return 0.12% 100% A+ 3% F
Total Return -26.22% 58% F 38% F
Trailing 12 Months  
Capital Gain -25.46% 67% D+ 43% F
Dividend Return 0.22% 100% A+ 3% F
Total Return -25.24% 67% D+ 43% F
Trailing 5 Years  
Capital Gain 124.76% 83% B 82% B-
Dividend Return 2.98% 100% A+ 8% F
Total Return 127.75% 83% B 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 27.54% 61% D- 83% B
Dividend Return 0.40% 100% A+ 12% F
Total Return 27.94% 61% D- 82% B-
Risk Return Profile  
Volatility (Standard Deviation) 36.04% 78% C+ 43% F
Risk Adjusted Return 77.54% 96% A 94% A
Market Capitalization 9.18B 96% A 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 34.44 44% F 26% F
Price/Book Ratio 9.46 16% F 9% F
Price / Cash Flow Ratio 32.52 18% F 10% F
EV/EBITDA 19.15 18% F 15% F
Management Effectiveness  
Return on Equity 27.50% 96% A 90% A-
Return on Invested Capital 14.22% 93% A 83% B
Return on Assets 8.36% 93% A 89% B+
Debt to Equity Ratio 112.65% 22% F 19% F
Technical Ratios  
Dividend Yield 0.32% 100% A+ 3% F
Short Ratio 3.66 57% F 47% F
Short Percent 3.30% 53% F 46% F
Beta 1.17 47% F 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector